Guideline Updates and Real-World Experiences in CLL: State-of-the-Art Evidence and Next Questions
The goal of this activity is to improve the knowledge, confidence, and performance of learners to integrate recent findings into the treatment of patients with CLL/SLL.
Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC
This program is intended for physicians, physician assistants, nurses, pharmacists, and other healthcare providers who care for patients with CLL/SLL.
Upon completion of this activity, participants should be able to:
- Design treatment plans for treatment-naive and relapsed/refractory CLL/SLL, including consideration of the agent’s toxicity profile, biomarkers, comorbidities, and patient preference
- Appraise intraclass differences among agents with the similar therapeutic target in CLL/SLL, regarding selectivity, target binding, efficacy, and adverse event profiles
- Evaluate the evolving role of measurable residual disease, allogeneic hematopoietic cell transplant, and CAR T-cell therapy
- Develop strategies to address unique clinical challenges and leverage an understanding of the current data and NCCN Guideline to optimize outcomes for patients with CLL/SLL
William G. Wierda, MD, PhD
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Jeremy S. Abramson, MD, MMSc
Department of Medicine
Harvard Medical School
Director, Center for Lymphoma
Massachusetts General Hospital
Anthony Mato, MD
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest. In addition, all faculty presentations have been reviewed to ensure education is fair and balanced and that clinical content presented supports safe, effective patient care. Individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter.
NCCN continuing education considers financial relationships to create a conflict of interest when an individual has both a financial relationship with a commercial interest and the opportunity to affect continuing education content about the products or services of a commercial interest with which he/she has a financial relationship.
NCCN continuing education considers relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
The faculty listed below discloses the following relevant financial relationships:
Jeremy S. Abramson, MD, MMSc, has disclosed that he has received consulting fees from AstraZeneca, BeiGene, Bluebird Bio, Celgene/Bristol-Myers Squibb, Epizyme, Genentech, Genmab, Incyte, Kite, and Kymera.
Anthony Mato, MD, MSCE, has disclosed that he has received funds for research support from AbbVie, Acerta/AstraZeneca, Adaptive, DTRM BioPharma, Johnson & Johnson, Loxo Oncology, Pharmacyclics, Regeneron, Sunesis, and TG Therapeutics and has received consulting fees from AbbVie, Acerta/AstraZeneca, Adaptive, Celgene, DTRM BioPharma, Johnson & Johnson, Pharmacyclics, Sunesis, TG Therapeutics, and Verastem.
William G. Wierda, MD, PhD, has disclosed that he has received funds for research support from AbbVie, Acerta, Cyclacel, Genentech, Gilead Sciences, Janssen, Juno, Kite, Loxo, miRagen, Novartis, Oncternal, Pharmacyclics, Sunesis, and Xencor.
The activity planning staff listed below discloses no relevant financial relationships:
CCO: Bing-E Xu, PhD; Timothy A. Quill, PhD; Megan Cartwright, PhD; Jason J. Everly, PharmD, BCOP, CHCP; Kevin Obholz, PhD; June Wasserstrom; Jim Mortimer
NCCN: Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Karen Kanefield; Kathy Ann Smith, CHCP
The NCCN clinical staff listed below discloses no relevant financial relationships:
Hema Sundar, PhD
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 1.5 contact hours.
NCCN designates this application-based continuing education activity for 1.5 contact hours (0.15 CEUs) of continuing education credit. UAN: JA4008196-0000-21-094-H01-P
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until July 22, 2022. PAs should only claim credit commensurate with the extent of their participation.
- 1.50 AAPA Category 1 CME credit
- 1.50 ACPE contact hours
- 1.50 AMA PRA Category 1 Credit™
- 1.50 ANCC contact hours
- 1.50 Participation
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing